Alkermes shares jump on news of another antipsychotic drug program; FDA sets PDUFA date on Orexigen's weight therapy;

@FierceBiotech: AbbVie adds a slate of $280M wagers on Seattle Genetics' "armed" antibody cancer tech. News | Follow @FierceBiotech

@JohnCFierce: Another SGLT2 drug arrives. Farxiga (dapagliflozin) from AZ. Release | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: AstraZeneca has made 3 deals in past 5 days. Today with Immunocore: Story. Yesterday was Horizon: News. | Follow @EmilyMFierce

> Shares of Alkermes ($ALKS) popped 6% this morning after the company announced that it is adding a new program for the antipsychotic aripiprazole lauroxil, which is now in late-stage development as a once-monthly product. This new program will develop the therapy to be dosed once every two months. Release

> The FDA has set the PDUFA deadline on Orexigen's ($OREX) weight loss drug Contrave for June 10. Story

> Daiichi Sankyo, Virtici and Celdara Medical have inked a collaboration pact on new drugs. Release

> XTL Biopharmaceuticals ($XTLB) has reached a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for Systemic Lupus Erythematosus. Release

Medical Device News

@FierceMedDev: India's Forus hauls in $8M for portable eye-screening device. More | Follow @FierceMedDev

@MichaelGFierce: Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: FiercePharma has gone mobile! Check out the new app here. | Follow @EmilyWFierce

@GalenMoore: Former Hologic CEO Cascella lands at rival DySIS. Story | Follow @GalenMoore

> Foundation Medicine teams up with Novartis for cancer diagnostics. Item

> ArthroCare will pay $30M to finally settle up with the feds. Story

> Analysts have high hopes for St. Jude in 2014. Article

Pharma News

@FiercePharma: Dean Hart, ex-Takeda VP sales, joins consulting firm Delta Point (Press Release) | Follow @FiercePharma

@TracyStaton: Most-read report at FiercePharma Tuesday: Top 10 Drug Patent Losses of 2014. More from FiercePharma | Follow @TracyStaton

@EricPFierce: Put FiercePharma in your pocket. Get the mobile app for iOS or Android here, fiercepharma.com/mobile | Follow @EricPFierce

@CarlyHFierce: Welcome to our newest addition to the Fierce Life Sciences team, associate editor Emily Wasserman! You can find her at @EmilyWFierce. | Follow @CarlyHFierce

> Teva trumps Endo's offer for patchmaker NuPathe. Is a bidding war next? Story

> Japan files a criminal action against Novartis for 'exaggerated' Diovan advertising Story

> Roche, Teva and AstraZeneca are all said to be in the mix to buy Celltrion Story

> Forest nabs Aptalis for $2.9B in its CEO's latest move toward a turnaround Story

Drug Delivery News

> Gene delivery method 'hijacks' tumor blood vessels. More

> How a single nanoparticle delivers two drugs separately to kill cancer cells. Story

> Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. Article

> Vaccine nanoparticles offer shake-and-bake field delivery. Report

> Armed with cancer drugs, white blood cells become cancer-killing sticky bombs. News

> India to require all changes in delivery to be regulated as a new drug. Item

Diagnostics News

> Metabolon names two new investors in its $15M Series E. More

> Foundation Medicine deepens its Novartis ties with new deal. News

> Maverix Biomics hauls in $6M for gene sequencing software. Item

> The market for noninvasive prenatal tests could triple by 2019, analysts say. Story

> Kindstar partners with Israeli BioView to bring lung cancer Dx to Asia. Report

> SRI bags $4.5M NIH contract to set up metabolomics outpost. Article

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.